

## Special Issue

# Cancer Pain—from Novel Mechanisms to Clinical Management

### Message from the Guest Editors

Cancer pain is a significant clinical challenge that greatly diminishes the quality of life for patients with advanced malignancies and complicates disease management. Conventional analgesics, such as NSAIDs and opioids, often provide inadequate relief and cause side effects, highlighting the need for new, mechanism-based therapies. This Special Issue, "Cancer Pain—From Novel Mechanisms to Clinical Management", seeks articles exploring innovative approaches to cancer pain management, from basic science to clinical applications. We welcome original research, reviews, and case studies in the following areas:

- Clinical Research: Emerging pharmaceutical interventions.
- Basic Science: New mechanisms and therapeutic targets in cancer pain.
- Reviews: Overviews of current and emerging therapies.

We aim to gather the latest research to improve the understanding and treatment of cancer pain. We look forward to your contributions.

---

### Guest Editors

Prof. Dr. Xuejun Song

Department of Medical Neuroscience and SUSTech Center for Pain Medicine, Southern University of Science and Technology, Shenzhen 518055, China

Dr. Xiaodong Liu

Department of Anaesthesia and Intensive Care, Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong

---

### Deadline for manuscript submissions

closed (25 December 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/218321](https://mdpi.com/si/218321)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)